Rakesh Kumar, F. Murad, O. Bogler, B. O’Malley, G. Hortobagyi
{"title":"John Mendelsohn: A visionary scientist, oncologist and leader","authors":"Rakesh Kumar, F. Murad, O. Bogler, B. O’Malley, G. Hortobagyi","doi":"10.18632/genesandcancer.195","DOIUrl":null,"url":null,"abstract":"Dr. John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients. During his professional journey, Dr. Mendelsohn also helped to build and elevate the status of three cancer cancers, all while touching the lives of cancer patients around the globe. He was a towering figure, and his passing in January 2019 casts a very long shadow over the entire field of cancer research and treatment. Although no one person can ever adequately fill John Mendelsohn's very large shoes, we can all learn by his remarkable example. Here we discuss Dr. Mendelsohn's professional life to spotlight his influence on oncology and also share personal reflections from us and several colleagues: Tony Hunter, Robert A. Weinberg, Robert C. Bast, Raymond Sawaya, David M. Gershenson, Christopher J Logothetis, Stanley R. Hamilton, Mien-Chie Hung, and George M. Stancel. See related article Kumar et al. Can Res 2019; 79:4315-4323.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":"10 1","pages":"109 - 118"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes and Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/genesandcancer.195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 3
Abstract
Dr. John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients. During his professional journey, Dr. Mendelsohn also helped to build and elevate the status of three cancer cancers, all while touching the lives of cancer patients around the globe. He was a towering figure, and his passing in January 2019 casts a very long shadow over the entire field of cancer research and treatment. Although no one person can ever adequately fill John Mendelsohn's very large shoes, we can all learn by his remarkable example. Here we discuss Dr. Mendelsohn's professional life to spotlight his influence on oncology and also share personal reflections from us and several colleagues: Tony Hunter, Robert A. Weinberg, Robert C. Bast, Raymond Sawaya, David M. Gershenson, Christopher J Logothetis, Stanley R. Hamilton, Mien-Chie Hung, and George M. Stancel. See related article Kumar et al. Can Res 2019; 79:4315-4323.
John Mendelsohn博士被认为是针对表皮生长因子受体(EGFR)的概念，提供了拮抗剂抗EGFR mAb抗癌活性的第一个证据，并为癌症患者开发了Erbitux(西妥昔单抗)药物。在他的职业生涯中，门德尔松博士还帮助建立和提升了三种癌症的地位，同时触动了全球癌症患者的生活。他是一位杰出的人物，他于2019年1月去世，给整个癌症研究和治疗领域蒙上了很长的阴影。虽然没有人能完全接替约翰·门德尔松的巨大职位，但我们都可以从他的杰出榜样中学习。在这里，我们将讨论门德尔松博士的职业生涯，以突出他对肿瘤学的影响，并分享我们和几位同事的个人反思:Tony Hunter, Robert A. Weinberg, Robert C. Bast, Raymond Sawaya, David M. Gershenson, Christopher J Logothetis, Stanley R. Hamilton, Mien-Chie Hung和George M. stansel。参见相关文章Kumar等人。Can Res 2019;79:4315 - 4323。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
